NIH Grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403

Cancer Targeted Technology announced that the NIH awarded CTT $1.44M on the second year of a competitive Small Business Innovation Research Phase IIB grant.
[Cancer Targeted Technology (Business Wire, Inc.)]
Press Release

Continue reading “NIH Grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403”

Bookmark

No account yet? Register

0
Share

BryoLogyx Announces Cooperative Research and Development Agreement for Bryostatin-1 with National Cancer Institute

BryoLogyx, Inc. announced that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute, to conduct a Phase I clinical trial with bryostatin-1 in pediatric and young adult patients with relapsing or refractory CD22 expressing acute lymphoblastic leukemia and lymphoma.
[BryoLogyx, Inc.]
Press Release

Continue reading “BryoLogyx Announces Cooperative Research and Development Agreement for Bryostatin-1 with National Cancer Institute”

Bookmark

No account yet? Register

0
Share

Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited announced that it has entered into a clinical trial collaboration with AstraZeneca to evaluate the combination of patritumab deruxtecan, a HER3 directed DXd antibody drug conjugate, and TAGRISSO, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer.
[Daiichi Sankyo Company, Limited]
Press Release

Continue reading “Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer”

Bookmark

No account yet? Register

0
Share

ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics

ORIC Pharmaceuticals, Inc. announced it has entered into an exclusive worldwide license agreement with Mirati Therapeutics, Inc. ORIC will have exclusive worldwide rights for the development activities and commercialization of a small molecule allosteric inhibitor program directed towards the polycomb repressive complex 2, a validated oncogenic target across several cancers with promising therapeutic potential in prostate cancer, among other indications.
[ORIC Pharmaceuticals, Inc.]
Press Release

Continue reading “ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics”

Bookmark

No account yet? Register

0
Share

Everest Medicines Announces First Patient Dosed in a Phase 1b/2 Study of FGF401 in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors

Everest Medicines has announced that the first patient has been dosed in a Phase Ib/II study evaluating FGF401 in combination with PD-1 inhibitor, pembrolizumab, in patients with advanced solid tumors, such as hepatocellular carcinoma.
[Everest Medicines]
Press Release

Continue reading “Everest Medicines Announces First Patient Dosed in a Phase 1b/2 Study of FGF401 in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors”

Bookmark

No account yet? Register

0
Share

European Commission grants marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima® SC, for an additional five indications including for use in inflammatory bowel disease and ankylosing spondylitis

Celltrion Healthcare announced that the European Commission has granted marketing authorisation for Remsima® subcutaneous formulation for the treatment of adult patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.
[Celltrion]
Press Release

Continue reading “European Commission grants marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima® SC, for an additional five indications including for use in inflammatory bowel disease and ankylosing spondylitis”

Bookmark

No account yet? Register

0
Share

Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China

Hutchison China MediTech Limited and Eli Lilly and Company announced an amendment to the 2013 License and Collaboration Agreement on Fruquintinib with Lilly Shanghai, an affiliate of Lilly. The 2020 Amendment covers the expansion of Chi-Med’s role in the commercialization of Elunate® in China.
[Hutchison China MediTech Limited]
Press Release

Continue reading “Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China”

Bookmark

No account yet? Register

0
Share

Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062

Daiichi Sankyo Company, Limited announced that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate, currently in Phase I clinical development for non-small cell lung cancer and TNBC.
[Daiichi Sankyo Ltd.]
Press Release

Continue reading “Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062”

Bookmark

No account yet? Register

0
Share

Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC)

Merck announced that the FDA has accepted two new supplemental Biologics License Applications for KEYTRUDA, Merck’s anti-PD-1 therapy.
[Merck]
Press Release

Continue reading “Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC)”

Bookmark

No account yet? Register

0
Share

BioAegis Therapeutics Initiates Phase II Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment

BioAegis Therapeutics, Inc. announced that it enrolled its first patient in its Phase II study of hospitalized patients with severe COVID-19 pneumonia.
[BioAegis Therapeutics, Inc. (GlobeNewswire, Inc.)]
Press Release

Continue reading “BioAegis Therapeutics Initiates Phase II Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment”

Bookmark

No account yet? Register

0
Share

IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase I Clinical Study

IMV, Inc. announced that Canadian government agencies will contribute up to CA$4.75 million to advance Phase I clinical development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel coronavirus SARS-COV-2.
[IMV, Inc.]
Press Release

Continue reading “IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase I Clinical Study”

Bookmark

No account yet? Register

0
Share

Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase III Study of Lenabasum for Treatment of Dermatomyositis

Corbus Pharmaceuticals Holdings, Inc. announced the completion of subject enrollment in DETERMINE, a Phase III study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis. The company expects to report topline results from this study in the fourth quarter of 2021.
[Corbus Pharmaceuticals Holdings, Inc.]
Full Article

Continue reading “Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase III Study of Lenabasum for Treatment of Dermatomyositis”

Bookmark

No account yet? Register

0
Share
Share